Thus, the novel bispecific antibody, faricimab (faricimab-svoa; VabysmoTM) targeting both VEGF-A and Ang-2, has been recently developed by Roche/Genentech for the treatment of w-AMD and DME [22]. This evidence concerns the gene VEGFA and age-related macular degeneration.